Brief: Ltr Pharma Says FDA Provides Path To Approval For Spontan
26/03/2025 01:31
March 26 (Reuters) - LTR Pharma Ltd LTP.AX: FDA PROVIDES PATH TO APPROVAL FOR SPONTAN Further company coverage: LTP.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ltr Pharma
See all newsAustralia's LTR Pharma surges as its drug begins US prescription fulfillment
Brief: LTR Pharma Executes Exclusive Pilot Agreement With Marius Pharmaceuticals, Inc For Kyzatrex
Brief: LTR Pharma Executes U.S. Commercial Agreement With Strive
Australia's LTR Pharma rises on commercial tie-up with US telehealth firm
Australia's LT Pharma gains after nod to test nasal spray